Dan has particular experience in pharmaceutical lifecycle management, both for marketed pharmaceutical products and for products in late-stage clinical development that require additional patent term.

For a venture-backed company repurposing a drug product that had earlier failed phase 3 clinical trials in a different indication, Dan designed a strategy for newly claiming the drug substance per se, including advice on new in vitro experiments, drafting, filing and prosecution of a new patent family, achieving allowance of Orange Book-listable claims shortly after acquisition of the company for $325 million upfront plus $120 million in contingent value rights.

More recently, for another venture-backed company, Dan designed a patent strategy that led to new drug substance and drug product claims for a complex mixture API in phase 1 clinical trials; the company was acquired for $200 million upfront, and the acquirer was then itself purchased for $1.2 billion.

For a now-public biotech conducting phase 3 trials for a small molecule drug long in development, Dan and collaborating experts engineered a robust next-generation patent estate that includes new late-expiring drug substance claims.

For a venture-backed company repurposing a drug candidate earlier shelved by a large pharma company and now in pivotal phase 3 trials, Dan and Fenwick colleagues have built a patent estate that covers the intended launch indication worldwide, and have continued to expand the scope to cover likely subsequent label expansions.